- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03649490
Advanced Materials Science in XLIF Study (AMS in XLIF)
A Prospective Multicenter Study Evaluating the Effect of Implant Material and/or Surface Structure on Progression of Fusion in XLIF® Surgery
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
Connecticut
-
Hartford, Connecticut, United States, 06106
- Hartford Healthcare Bone and Joint Institute
-
-
Florida
-
Jacksonville, Florida, United States, 32207
- Lyerly Neurosurgery
-
Tampa, Florida, United States, 33606
- University of South Florida Department of Neurosurgery, Tampa General Hospital
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush University Medical Center
-
-
Kentucky
-
Paducah, Kentucky, United States, 42001
- Orthopaedic Institute of Western Kentucky
-
-
Maryland
-
Bethesda, Maryland, United States, 20814
- Suburban Hospital, Johns Hopkins Medicine
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
-
Missouri
-
Columbia, Missouri, United States, 65201
- Columbia Orthopedic Group Research
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28207
- OrthoCarolina
-
Durham, North Carolina, United States, 27710
- Duke University
-
Wilmington, North Carolina, United States, 28401
- Atlantic Brain and Spine
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73114
- The Spine Clinic of OKC
-
-
Texas
-
San Antonio, Texas, United States, 78229
- UT Health San Antonio
-
-
Virginia
-
Charlottesville, Virginia, United States, 22903
- University of Virginia Health System
-
-
Washington
-
Kirkland, Washington, United States, 98034
- Evergreen Health
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male and female patients who are 18-80 years of age;
Planned interbody fusion surgery, including at least one level of extreme lateral interbody fusion (XLIF) prior to enrollment in the research at one or two consecutive lumbar levels for degenerative disc disease, including those with up to Grade 2 spondylolisthesis, with one of the following NuVasive, Inc. interbody implants:
- Coroent® XL PEEK interbody implant; or
- Modulus® 3D-printed titanium interbody implant; or
- Cohere® XLIF Porous PEEKTM interbody implant.
If a transforaminal lumbar interbody fusion or anterior lumbar interbody fusion (TLIF or ALIF) is planned adjacent to the XLIF level, the same NuVasive, Inc. interbody implant material type must be used as determined by the implant enrollment schedule. For example:
- Smooth PEEK: Coroent XL PEEK (XLIF) + Coroent L (TLIF) or Coroent XLR (ALIF) or Brigade (ALIF)
- 3D-printed titanium: Modulus XLIF + Modulus TLIF or Modulus ALIF
- Porous PEEK: Cohere XLIF + Coalesce TLIF (currently no ALIF option)
- The planned procedure must include placement of bilateral posterior screw fixation with or without intrafacet fusion using autograft (with or without the assigned allograft used at the XLIF level(s)) at the treated level(s). Direct posterior decompression at the index interbody fusion level(s) is acceptable.
- Preoperative coronal Cobb angle of < 10°;
- Able to undergo surgery based on physical exam, medical history, and surgeon judgment;
- Understands the conditions of enrollment and willing to sign an informed consent to participate in the evaluation.
Exclusion Criteria:
- Use of BMP, synthetic bone graft substitutes, allografts, or any other graft material in the interbody or intrafacet spaces other than those under study;
- Posterior grafting other than the allowed intrafacet fusion at the treated level(s);
- Revision of prior fusion at treated level(s) (adjacent level interbody fusion is acceptable);
- XLIF procedure that requires or results in the release of the anterior longitudinal ligament or posterior osteotomy;
- Preoperative coronal Cobb angle of ≥ 10°;
- Procedures performed with XLIF interbody implants with integrated vertebral body screw(s);
- Active smoking six (6) weeks prior to surgery;
- Systemic or local infection (active or latent);
- Diseases that significantly inhibit bone healing (e.g., prior diagnosis of osteoporosis, metabolic bone disease, uncontrolled diabetes, dialysis dependent renal failure, symptomatic liver disease);
- Rheumatoid arthritis or other autoimmune disease that, in the option of the investigator, would interfere with bone healing and/or fusion;
- Treatment with pharmaceuticals interfering with calcium metabolism;
- Undergoing chemotherapy or radiation treatment or chronic use of steroids (defined as more than 6 weeks of steroid use within 12 months of surgery or anytime postoperatively, other than episodic use or inhaled corticosteroids);
- Use of bone stimulators postoperatively;
- Non-ambulatory, wheelchair-bound;
- Involvement in active litigation relating to the spine (worker's compensation claim is allowed if it is not contested);
- Significant general illness (e.g., HIV, active metastatic cancer of any type, uncontrolled diabetes, dialysis dependent renal failure, symptomatic liver disease);
- Spinal metastases or active spinal tumor malignancy;
- Immunocompromised or is being treated with immunosuppressive agents;
- Pregnant, or plans to become pregnant during the study;
- Mental or physical condition that would limit the ability to comply with study requirements;
- Prisoners;
- Participating in another clinical study that would confound study data.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Smooth PEEK Interbody Implants in XLIF
Smooth PEEK interbody implants for XLIF (with allograft chips and BMA or cancellous allograft) provide maximum surface area and structural stability with large central apertures to allow bony through-growth.
Multiple length options enable optimal apophyseal support, thus reducing the chance of subsidence.
Additionally, lordotic profiles are available to induce proper sagittal alignment.
|
3D-Printed Titanium Interbody Implants in XLIF
3D-printed, fully porous titanium interbody implants for XLIF (with allograft chips and BMA or cancellous allograft) have a porous architecture that mimics the porosity and stiffness of bone for reduced stress shielding and improved radiographic imaging.
The advanced microporous surface topography creates an ideal environment for bone in-growth.
|
Porous PEEK Interbody Implants in XLIF
Porous PEEK interbody implants for XLIF (with allograft chips and BMA or cancellous allograft) combine the osseointegration capabilities of porous metal implants with the favorable imaging and mechanical properties of traditional PEEK implants.
The Porous PEEK architecture, with 60% porosity and 300 mm average pore size, is specifically tailored to elicit the optimal osteogenic cell response and promote bone tissue ingrowth inside the pores, as demonstrated in preclinical studies.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Radiographic Fusion Success
Time Frame: 24 months
|
The proportion of subjects with apparent radiographic fusion at or before 24 months within each treatment group
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MCID and SCB threshold for each PRO: VAS (back/leg pain), ODI, and EQ-5D, within each treatment group
Time Frame: 3, 6, 12, and 24 months
|
Percentage of subjects meeting minimal clinically important difference (MCID) and substantial clinical benefit (SCB) thresholds for each patient-reported outcome (PRO): Back and leg pain (visual analog scale (VAS)), disability (Oswestry disability index (ODI)), and quality of life (EQ-5D) within each treatment group.
|
3, 6, 12, and 24 months
|
Fusion Rates at Follow-up Timepoints
Time Frame: 6, 12, 24 months
|
Percentage of subjects with a successful radiographic interbody fusion by each follow-up timepoint (6, 12, and 24-month postoperative follow-up)
|
6, 12, 24 months
|
Maintenance of Radiographic Correction
Time Frame: 3, 6, 12, and 24 months
|
Percentage of subjects with maintenance of radiographic correction out to 24-months postoperative follow-up within each treatment group
|
3, 6, 12, and 24 months
|
Complications
Time Frame: 3, 6, 12, and 24 months
|
Rate of complications attributable to the use of the interbody implants to be studied
|
3, 6, 12, and 24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Kyle Malone, MS, NuVasive
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NUVA.X1801
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Degenerative Disc Disease
-
Assistance Publique - Hôpitaux de ParisTerminatedCervical Degenerative Disc Disease | Kyphosis | Lumbar Degenerative Disc DiseaseFrance
-
Assiut UniversityNot yet recruiting
-
Spine BioPharma, IncMCRARecruitingLumbar Degenerative Disc DiseaseUnited States
-
AxioMed Spine CorporationUnknownDegenerative Disc Disease (DDD)United States, Germany
-
Synthes USA HQ, Inc.CompletedLumbar Degenerative Disc Disease
-
DePuy InternationalTerminatedCervical Degenerative Disc DiseaseAustralia, Germany, Italy, Malaysia, Netherlands, Spain, United Kingdom
-
Synergy Spine SolutionsMCRARecruitingCervical Degenerative Disc DiseaseUnited States
-
Orthofix Inc.TerminatedCervical Degenerative Disc DiseaseUnited States
-
Yuhan CorporationCompletedDisc Degenerative DiseaseKorea, Republic of
-
Synergy Spine SolutionsMCRANot yet recruitingCervical Degenerative Disc DiseaseUnited Kingdom